The 2025 ESE Menopause Guidelines: A Practitioner's Guide

In October 2025, the European Society of Endocrinology (ESE) published its first comprehensive Clinical Practice Guideline for Management and Evaluation of Menopause and the Perimenopause in the European Journal of Endocrinology. It was endorsed by the Endocrine Society, the European Menopause and Andropause Society (EMAS), and the British Menopause Society — making it one of the most broadly co-signed menopause guidelines published this decade.

For non-prescribing practitioners, the guideline is a useful tool even though it sits outside your scope. It clarifies what conventional medicine is now offering clients, what the diagnostic standards are, and where the gaps remain — gaps that practitioners working in lifestyle, nutrition, and root-cause care are uniquely positioned to fill.

Here's the practitioner-relevant breakdown.

What changed at the diagnostic standard

The most practical shift for assessment is around biochemical testing:

• In women over 45 with characteristic symptoms, biochemical testing is not needed for diagnosis or management. The guideline reaffirms what experienced clinicians have known for years — FSH and estradiol are too variable in perimenopause to be diagnostically useful, and the diagnosis is fundamentally clinical.
• In women under 40 with relevant symptoms,biochemical testing for premature ovarian insufficiency (POI) is recommended. This is a meaningful threshold: under-40s presenting with cycle changes, hot flashes, or sleep disruption should be screened, not dismissed as “too young.”
• Between 40 and 45, testing falls in a grey zone where clinical judgment matters most. Symptoms plus cycle pattern carry more weight than a single lab snapshot.

The benefit-risk recalibration for MHT

The headline recommendation across the 2025 guidelines:

For most healthy, symptomatic women under the age of 60 who are within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks.

This continues the post-WHI re-evaluation that has been ongoing for more than a decade. The major recalibrations from the 2025 document:

• Vasomotor symptoms (VMS):MHT remains the most effective treatment. Non-hormonal alternatives are now also clearly framed (gabapentin, SSRIs, fezolinetant, lifestyle), and the guideline emphasizes choice based on the patient's risk profile, not a default-to-MHT or default-against-MHT posture.
• Genitourinary syndrome of menopause (GSM):Local vaginal estrogen is endorsed for vaginal dryness, painful sex, and recurrent UTIs — including for women who have contraindications to systemic MHT. This is a notable expansion of who's considered eligible.
• Bone loss and fracture prevention: MHT is now explicitly recognized as an effective bone-protective intervention for women in this window, not just a symptom-management tool.
• Shared decision-making is emphasized throughout. The guideline directs prescribers to build personalized treatment plans and re-evaluate them periodically based on age, time since menopause, and individual risk stratification.

Where the practitioner fits in

Your role isn't to write prescriptions — but the 2025 guideline actually creates several openings for non-prescribing practitioners to do more meaningful work:

1. Pre-decision support

Many women approach the MHT decision without a clear understanding of their own baseline metabolic, gut, and stress-response status. They ask their provider “should I do hormone therapy?” without having any of the foundational systems in working order. Practitioners can support the decision by helping a client:

• Establish blood sugar regulation, gut function, and stress modulation before starting MHT (so any symptom changes are attributable, not muddied)
• Identify which symptoms are most disruptive and likely to respond to MHT vs. which are likely to need other interventions
• Frame realistic expectations — MHT is not a cure-all, and lifestyle foundations remain non-negotiable

2. Adjunct protocols during MHT

The 2025 guideline is explicit that lifestyle interventions remain central even when MHT is used. Practitioners are uniquely positioned to do this work:

• Targeted nutrition for blood sugar, cortisol rhythm, and body composition
• Sleep hygiene and circadian rhythm support (often a faster win than MHT adjustment)
• Stress-modulating practices, vagal-tone work, and HPA-axis recovery
• Liver support for hormone metabolism (especially in clients on oral estrogens that undergo first-pass metabolism)
• Gut microbiome support — the estrobolome influences how the body handles both endogenous estrogen and supplemented hormones

3. Symptom triage

Many clients try MHT and feel partially improved but still symptomatic. The 2025 guideline directs prescribers to re-evaluate periodically, but that re-evaluation often takes 3-6 months between visits. Practitioners working with clients weekly or monthly are the ones who notice patterns first — a client whose mood symptoms didn't respond to estrogen but did respond to magnesium and B6, or a client whose sleep got worse on a particular progestin, or one whose joint pain only resolved after adding an anti-inflammatory protocol alongside MHT.

Document these patterns. Communicate them respectfully (within scope) to the prescribing provider. The 2025 guideline framework actively invites this kind of multidisciplinary input — “shared decision-making” isn't just doctor-and-patient, it's doctor-and-patient-and-the-rest-of-the-care-team.

4. The MHT off-ramp

The guideline emphasizes periodic reevaluation and risk restratification. That means some women on MHT will eventually taper off. Practitioners can support the transition with structured lifestyle scaffolding — gut, liver, blood sugar, and stress protocols designed to maintain symptom control as exogenous hormones come down.

The remaining gaps

For all its strengths, the 2025 ESE guideline is conservative on several fronts where practitioner work is meaningful:

• Perimenopausal hormone testing: The guideline essentially leaves testing alone for the 40-45 transition. Functional testing (DUTCH, salivary panels, cycle-phase-specific serum) sits outside the scope but provides meaningful pattern data for practitioners working in this window.
• Symptoms not yet considered “menopausal”: Brain fog, anxiety, joint pain, and mood lability often appear well before the textbook hot flashes. The guideline acknowledges these but doesn't fully integrate them into the diagnostic picture.
• Cyclical / physiologic HRT dosing: The mainstream guideline framework still defaults to continuous static dosing for most patients. The emerging conversation around physiologic / cyclical dosing (mimicking the natural cycle) gets little attention here.
• Long-term lifestyle:MHT is recommended for the symptomatic window, but the post-MHT decades get less guidance. This is the practitioner's territory.

How to use the guideline in your practice

A few concrete moves you can make today:

1. Read the executive summary. Even at high level, you want to be able to cite the 2025 ESE document when clients ask about hormone therapy. Being current with the literature builds trust.
2. Add a perimenopause/menopause screening flow to your intake. Symptoms + age + cycle pattern. If a client under 40 is symptomatic, route them to a POI screening referral.
3. Build a referral relationship with at least one local prescriber who follows the 2025 guideline (vs. older, MHT-skeptical providers). Your work converts better when the downstream care matches your framing.
4. Educate proactively. Many clients are still scared of MHT because of headlines from the 2002 WHI study. A 30-minute conversation about how the evidence base has shifted in the last 20 years can be the most useful thing you do for them.

The takeaway

The 2025 ESE guideline isn't a revolution — it's a careful, well-cited consolidation of where conventional menopause medicine has been heading for a decade. For practitioners, the value isn't the prescribing protocols (those aren't yours) but the diagnostic framework, the explicit acknowledgment of lifestyle as adjunctive, and the gaps that point directly to the work you're already doing.

Read it. Cite it. Use it to elevate the conversations you're already having with clients.